Natural Killer (NK) Cell Therapeutics Market Size, Growth & Statistics

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Natural Killer (NK) Cell Therapeutics Market Size Analysis

Global Natural Killer (NK) Cell Therapeutics Market Introduction
By Natural Killer (NK) cell Therapy Type
1. Introduction
  1. Natural Killer (NK) cell Therapy Type By Value
2. NK Cell Therapy (unmodified)
  1. By Value
3. CAR-NK Cell Therapy (modified)
  1. By Value
4. NK Cell Engager
  1. By Value
By Approaches
1. Introduction
  1. Approaches By Value
2. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
  1. By Value
3. Bispecific Antibodies
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Cancer
  1. By Value
3. Immunoproliferative Disorders
  1. By Value
4. Acute Infectious Diseases
  1. By Value
5. Gastrointestinal Diseases
  1. By Value
6. Others
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Hepatocellular Carcinoma (HCC)
  1. By Value
3. Acute Myeloid Leukemia (AML)
  1. By Value
4. Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)
  1. By Value
5. Peripheral T-Cell Lymphoma (PTCL).
  1. By Value
By Pipeline Product
1. Introduction
  1. Pipeline Product By Value
2. AFM13
  1. By Value
3. MG4101
  1. By Value
4. GTA002 (oNKordA)
  1. By Value
5. TAK-007
  1. By Value

North America Market Analysis

Introduction
By Natural Killer (NK) cell Therapy Type
1. Introduction
  1. Natural Killer (NK) cell Therapy Type By Value
2. NK Cell Therapy (unmodified)
  1. By Value
3. CAR-NK Cell Therapy (modified)
  1. By Value
4. NK Cell Engager
  1. By Value
By Approaches
1. Introduction
  1. Approaches By Value
2. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
  1. By Value
3. Bispecific Antibodies
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Cancer
  1. By Value
3. Immunoproliferative Disorders
  1. By Value
4. Acute Infectious Diseases
  1. By Value
5. Gastrointestinal Diseases
  1. By Value
6. Others
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Hepatocellular Carcinoma (HCC)
  1. By Value
3. Acute Myeloid Leukemia (AML)
  1. By Value
4. Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)
  1. By Value
5. Peripheral T-Cell Lymphoma (PTCL).
  1. By Value
By Pipeline Product
1. Introduction
  1. Pipeline Product By Value
2. AFM13
  1. By Value
3. MG4101
  1. By Value
4. GTA002 (oNKordA)
  1. By Value
5. TAK-007
  1. By Value
U.S.
1. By Natural Killer (NK) cell Therapy Type
  1. Introduction
    1. Natural Killer (NK) cell Therapy Type By Value
  2. NK Cell Therapy (unmodified)
    1. By Value
  3. CAR-NK Cell Therapy (modified)
    1. By Value
  4. NK Cell Engager
    1. By Value
2. By Approaches
  1. Introduction
    1. Approaches By Value
  2. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
    1. By Value
  3. Bispecific Antibodies
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Cancer
    1. By Value
  3. Immunoproliferative Disorders
    1. By Value
  4. Acute Infectious Diseases
    1. By Value
  5. Gastrointestinal Diseases
    1. By Value
  6. Others
    1. By Value
4. By Indication
  1. Introduction
    1. Indication By Value
  2. Hepatocellular Carcinoma (HCC)
    1. By Value
  3. Acute Myeloid Leukemia (AML)
    1. By Value
  4. Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)
    1. By Value
  5. Peripheral T-Cell Lymphoma (PTCL).
    1. By Value
5. By Pipeline Product
  1. Introduction
    1. Pipeline Product By Value
  2. AFM13
    1. By Value
  3. MG4101
    1. By Value
  4. GTA002 (oNKordA)
    1. By Value
  5. TAK-007
    1. By Value
Canada

Europe Market Analysis

Introduction
By Natural Killer (NK) cell Therapy Type
1. Introduction
  1. Natural Killer (NK) cell Therapy Type By Value
2. NK Cell Therapy (unmodified)
  1. By Value
3. CAR-NK Cell Therapy (modified)
  1. By Value
4. NK Cell Engager
  1. By Value
By Approaches
1. Introduction
  1. Approaches By Value
2. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
  1. By Value
3. Bispecific Antibodies
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Cancer
  1. By Value
3. Immunoproliferative Disorders
  1. By Value
4. Acute Infectious Diseases
  1. By Value
5. Gastrointestinal Diseases
  1. By Value
6. Others
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Hepatocellular Carcinoma (HCC)
  1. By Value
3. Acute Myeloid Leukemia (AML)
  1. By Value
4. Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)
  1. By Value
5. Peripheral T-Cell Lymphoma (PTCL).
  1. By Value
By Pipeline Product
1. Introduction
  1. Pipeline Product By Value
2. AFM13
  1. By Value
3. MG4101
  1. By Value
4. GTA002 (oNKordA)
  1. By Value
5. TAK-007
  1. By Value
U.K.
1. By Natural Killer (NK) cell Therapy Type
  1. Introduction
    1. Natural Killer (NK) cell Therapy Type By Value
  2. NK Cell Therapy (unmodified)
    1. By Value
  3. CAR-NK Cell Therapy (modified)
    1. By Value
  4. NK Cell Engager
    1. By Value
2. By Approaches
  1. Introduction
    1. Approaches By Value
  2. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
    1. By Value
  3. Bispecific Antibodies
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Cancer
    1. By Value
  3. Immunoproliferative Disorders
    1. By Value
  4. Acute Infectious Diseases
    1. By Value
  5. Gastrointestinal Diseases
    1. By Value
  6. Others
    1. By Value
4. By Indication
  1. Introduction
    1. Indication By Value
  2. Hepatocellular Carcinoma (HCC)
    1. By Value
  3. Acute Myeloid Leukemia (AML)
    1. By Value
  4. Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)
    1. By Value
  5. Peripheral T-Cell Lymphoma (PTCL).
    1. By Value
5. By Pipeline Product
  1. Introduction
    1. Pipeline Product By Value
  2. AFM13
    1. By Value
  3. MG4101
    1. By Value
  4. GTA002 (oNKordA)
    1. By Value
  5. TAK-007
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Natural Killer (NK) cell Therapy Type
1. Introduction
  1. Natural Killer (NK) cell Therapy Type By Value
2. NK Cell Therapy (unmodified)
  1. By Value
3. CAR-NK Cell Therapy (modified)
  1. By Value
4. NK Cell Engager
  1. By Value
By Approaches
1. Introduction
  1. Approaches By Value
2. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
  1. By Value
3. Bispecific Antibodies
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Cancer
  1. By Value
3. Immunoproliferative Disorders
  1. By Value
4. Acute Infectious Diseases
  1. By Value
5. Gastrointestinal Diseases
  1. By Value
6. Others
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Hepatocellular Carcinoma (HCC)
  1. By Value
3. Acute Myeloid Leukemia (AML)
  1. By Value
4. Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)
  1. By Value
5. Peripheral T-Cell Lymphoma (PTCL).
  1. By Value
By Pipeline Product
1. Introduction
  1. Pipeline Product By Value
2. AFM13
  1. By Value
3. MG4101
  1. By Value
4. GTA002 (oNKordA)
  1. By Value
5. TAK-007
  1. By Value
China
1. By Natural Killer (NK) cell Therapy Type
  1. Introduction
    1. Natural Killer (NK) cell Therapy Type By Value
  2. NK Cell Therapy (unmodified)
    1. By Value
  3. CAR-NK Cell Therapy (modified)
    1. By Value
  4. NK Cell Engager
    1. By Value
2. By Approaches
  1. Introduction
    1. Approaches By Value
  2. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
    1. By Value
  3. Bispecific Antibodies
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Cancer
    1. By Value
  3. Immunoproliferative Disorders
    1. By Value
  4. Acute Infectious Diseases
    1. By Value
  5. Gastrointestinal Diseases
    1. By Value
  6. Others
    1. By Value
4. By Indication
  1. Introduction
    1. Indication By Value
  2. Hepatocellular Carcinoma (HCC)
    1. By Value
  3. Acute Myeloid Leukemia (AML)
    1. By Value
  4. Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)
    1. By Value
  5. Peripheral T-Cell Lymphoma (PTCL).
    1. By Value
5. By Pipeline Product
  1. Introduction
    1. Pipeline Product By Value
  2. AFM13
    1. By Value
  3. MG4101
    1. By Value
  4. GTA002 (oNKordA)
    1. By Value
  5. TAK-007
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Natural Killer (NK) cell Therapy Type
1. Introduction
  1. Natural Killer (NK) cell Therapy Type By Value
2. NK Cell Therapy (unmodified)
  1. By Value
3. CAR-NK Cell Therapy (modified)
  1. By Value
4. NK Cell Engager
  1. By Value
By Approaches
1. Introduction
  1. Approaches By Value
2. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
  1. By Value
3. Bispecific Antibodies
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Cancer
  1. By Value
3. Immunoproliferative Disorders
  1. By Value
4. Acute Infectious Diseases
  1. By Value
5. Gastrointestinal Diseases
  1. By Value
6. Others
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Hepatocellular Carcinoma (HCC)
  1. By Value
3. Acute Myeloid Leukemia (AML)
  1. By Value
4. Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)
  1. By Value
5. Peripheral T-Cell Lymphoma (PTCL).
  1. By Value
By Pipeline Product
1. Introduction
  1. Pipeline Product By Value
2. AFM13
  1. By Value
3. MG4101
  1. By Value
4. GTA002 (oNKordA)
  1. By Value
5. TAK-007
  1. By Value
UAE
1. By Natural Killer (NK) cell Therapy Type
  1. Introduction
    1. Natural Killer (NK) cell Therapy Type By Value
  2. NK Cell Therapy (unmodified)
    1. By Value
  3. CAR-NK Cell Therapy (modified)
    1. By Value
  4. NK Cell Engager
    1. By Value
2. By Approaches
  1. Introduction
    1. Approaches By Value
  2. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
    1. By Value
  3. Bispecific Antibodies
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Cancer
    1. By Value
  3. Immunoproliferative Disorders
    1. By Value
  4. Acute Infectious Diseases
    1. By Value
  5. Gastrointestinal Diseases
    1. By Value
  6. Others
    1. By Value
4. By Indication
  1. Introduction
    1. Indication By Value
  2. Hepatocellular Carcinoma (HCC)
    1. By Value
  3. Acute Myeloid Leukemia (AML)
    1. By Value
  4. Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)
    1. By Value
  5. Peripheral T-Cell Lymphoma (PTCL).
    1. By Value
5. By Pipeline Product
  1. Introduction
    1. Pipeline Product By Value
  2. AFM13
    1. By Value
  3. MG4101
    1. By Value
  4. GTA002 (oNKordA)
    1. By Value
  5. TAK-007
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Natural Killer (NK) cell Therapy Type
1. Introduction
  1. Natural Killer (NK) cell Therapy Type By Value
2. NK Cell Therapy (unmodified)
  1. By Value
3. CAR-NK Cell Therapy (modified)
  1. By Value
4. NK Cell Engager
  1. By Value
By Approaches
1. Introduction
  1. Approaches By Value
2. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
  1. By Value
3. Bispecific Antibodies
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Cancer
  1. By Value
3. Immunoproliferative Disorders
  1. By Value
4. Acute Infectious Diseases
  1. By Value
5. Gastrointestinal Diseases
  1. By Value
6. Others
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Hepatocellular Carcinoma (HCC)
  1. By Value
3. Acute Myeloid Leukemia (AML)
  1. By Value
4. Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)
  1. By Value
5. Peripheral T-Cell Lymphoma (PTCL).
  1. By Value
By Pipeline Product
1. Introduction
  1. Pipeline Product By Value
2. AFM13
  1. By Value
3. MG4101
  1. By Value
4. GTA002 (oNKordA)
  1. By Value
5. TAK-007
  1. By Value
Brazil
1. By Natural Killer (NK) cell Therapy Type
  1. Introduction
    1. Natural Killer (NK) cell Therapy Type By Value
  2. NK Cell Therapy (unmodified)
    1. By Value
  3. CAR-NK Cell Therapy (modified)
    1. By Value
  4. NK Cell Engager
    1. By Value
2. By Approaches
  1. Introduction
    1. Approaches By Value
  2. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
    1. By Value
  3. Bispecific Antibodies
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Cancer
    1. By Value
  3. Immunoproliferative Disorders
    1. By Value
  4. Acute Infectious Diseases
    1. By Value
  5. Gastrointestinal Diseases
    1. By Value
  6. Others
    1. By Value
4. By Indication
  1. Introduction
    1. Indication By Value
  2. Hepatocellular Carcinoma (HCC)
    1. By Value
  3. Acute Myeloid Leukemia (AML)
    1. By Value
  4. Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)
    1. By Value
  5. Peripheral T-Cell Lymphoma (PTCL).
    1. By Value
5. By Pipeline Product
  1. Introduction
    1. Pipeline Product By Value
  2. AFM13
    1. By Value
  3. MG4101
    1. By Value
  4. GTA002 (oNKordA)
    1. By Value
  5. TAK-007
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Natural Killer (NK) Cell Therapeutics Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

GC Cell (GC Biopharma corp.)
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
ImmunityBio Inc.
Nkarta Inc.
Takeda Pharmaceutical Company Limited
Sanofi S. A.
Innate Pharma SA
Glycostem Therapeutics B. V.
Fate Therapeutics Inc.
Dragonfly Therapeutics Inc.
Cytovac A/ S.

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment